1 |
Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135-140.
DOI
|
2 |
Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48:249-253.
DOI
|
3 |
Yun JH, Ham JW, Park JE, Kim CK. Experimental study on the potency-maintaining periods of reconstituted botulinum type A toxin. J Korean Dent Assoc 2005;43:119-125.
|
4 |
Kazim NA, Black EH. Botox: shaken, not stirred. Ophthalmic Plast Reconstr Surg 2008;24:10-12.
DOI
|
5 |
Trindade De Almeida AR, Kadunc BV, Di Chiacchio N, Neto DR. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg 2003;29:530-531; discussion 532.
DOI
|
6 |
Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203:1-60.
DOI
|
7 |
Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77.
DOI
|
8 |
Cichon JV Jr, McCaffrey TV, Litchy WJ, Knops JL. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 1995;105:144-148.
DOI
|
9 |
Ekong TA, Feavers IM, Sesardic D. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 1997;143:3337-3347.
DOI
|
10 |
Sesardic D, McLellan K, Ekong TA, Das RG. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol Toxicol 1996;78:283-288.
DOI
|
11 |
Ghosh MN. Fundamentals of experimental pharmacology. 2nd ed. Calcutta: Scientific Book Agency; 1984. pp. 187-189.
|
12 |
Kim JY, Kim ST, Cho SW, Jung HS, Park KT, Son HK. Growth effects of botulinum toxin type A injected into masseter muscle on a developing rat mandible. Oral Dis 2008;14:626-632.
DOI
|
13 |
Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-770.
|
14 |
Mclellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34:975-985.
DOI
|
15 |
Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99.
DOI
|
16 |
Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol 1992;58:3426-3428.
DOI
|
17 |
Randhawa MA. Calculation of LD50 values from the method of Miller and Tainter, 1944. J Ayub Med Coll Abbottabad 2009;21:184-185.
|
18 |
Finney DJ. Probit analysis. 2nd ed. Cambridge: Cambridge University Press; 1952.
|
19 |
Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg 1996;22:39-43.
DOI
|